Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)

China flag China · Delayed Price · Currency is CNY
101.45
-3.05 (-2.92%)
May 8, 2026, 3:00 PM CST
Market Cap26.85B +4.6%
Revenue (ttm)1.55B +52.1%
Net Income497.93M
EPS1.88
Shares Out264.71M
PE Ratio53.94
Forward PE48.46
Dividendn/a
Ex-Dividend Daten/a
Volume3,306,940
Average Volume3,563,447
Open106.01
Previous Close104.50
Day's Range100.93 - 106.65
52-Week Range75.10 - 134.17
Beta0.02
RSI54.65
Earnings DateApr 29, 2026

About SHA:688266

Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tablets for hepatocellular carcinoma and iodine-refractory differentiated thyroid cancer; recombinant human thrombin for hemostasis; and jacktinib tablets for intermediate and high-risk myelofibrosis. It also develops drug candidates in the NDA, Phase III, or registration clinical trial stages, such as gecacitinib hydroch... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 1,055
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688266
Full Company Profile

Financial Performance

In 2025, SHA:688266's revenue was 810.48 million, an increase of 52.07% compared to the previous year's 532.95 million. Losses were -162.95 million, 18.2% more than in 2024.

Financial Statements